Sundberg I, et al. - The psychiatric side effects of new interferon (IFN)-free treatment for hepatitis C virus (HCV) (including depressive symptoms and sleep) were investigated in real world patients also including those with a history of psychiatric diagnosis, substance abuse or drug dependence. Researchers monitored 17 consecutive patients during treatment with three of the latest direct-acting antiviral (DAA) agents (sofosbuvir, simeprevir and daclatasvir). A history of any psychiatric diagnosis was noted in 15/17 patients (88%) at baseline. They noted DAA treatment completion in the study patients without substantial psychiatric side effects despite a history of affective disorder, drug abuse or neuropsychiatric disorder and previous IFN-based treatment in the majority of patients. Reduction in depressive symptoms after DAA treatment was also noted. Results thus supported DAAs treatment in HCV patients with psychiatric comorbidity with good efficacy and without psychiatric side effects.